Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

Type Journal Article Author Michael A. Matthay Author B. Taylor Thompson URL https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/abstract Publication The Lancet Respiratory Medicine ISSN 2213-2600, 2213-2619 Date 29/10/2020 Extra Publisher: Elsevier PMID: 33129421 Journal Abbr The Lancet Respiratory Medicine DOI 10.1016/S2213-2600(20)30503-8 Library Catalog www.thelancet.com Language English Abstract The impressive results of the RECOVERY trial established that a moderate dose of dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with COVID-19 and respiratory failure who required therapy with supplemental oxygen or mechanical ventilation.1 The data also indicated that dexamethasone might increase mortality in hospitalised patients who were not receiving oxygen. This landmark trial and the subsequent practice guidelines from several academic and health organisations recommending dexamethasone use in patients with severe COVID-19 have changed clinical practice for hospitalised patients on supplemental oxygen or mechanical ventilation. Short Title Dexamethasone in hospitalised patients with COVID-19